The FDA has reclassified radiological computer-assisted detection (CAD) and diagnosis (CADx) software from class III (highest risk) to class II (special controls).
Key Details
- 1The FDA finalized the order on June 13, moving CAD/CADx software used in radiology to class II regulation.
- 2Devices affected include software aiding detection and diagnosis on medical images like CT, MRI, and X-ray.
- 3Special controls now apply, such as design verification, validation, and clear labeling requirements.
- 4This change lowers the regulatory burden, enabling access via the 510(k) process instead of De Novo or PMA routes.
- 5Reclassification intends to maintain safety and effectiveness while enhancing patient and industry access to innovative tools.
Why It Matters
This regulatory change will significantly streamline the approval process for imaging AI developers, reducing time-to-market and promoting innovation. For radiologists, it could lead to faster clinical adoption of advanced CAD tools, with maintained safety standards.
Source
AuntMinnie
Related News
•AuntMinnie
Deep Learning AI Outperforms Radiologists in Detecting ENE on CT
A deep learning tool, DeepENE, exceeded radiologist performance in identifying lymph node extranodal extension in head and neck cancers using preoperative CT scans.
•Radiology Business
FDA Clears Multi-Disease AI Screening Platform for CT Imaging
HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
•AuntMinnie
AI Projected to Reshape Radiologist Workload But Not Eliminate Jobs
Stanford researchers predict AI could reduce radiologist hours by up to 49% over the next five years, though workforce size is likely to remain stable due to rising imaging demand.